Novavax appoints Stanley Erck chief executive
pharmafile | April 20, 2011 | Appointment | Research and Development |Â Â appointment, research and developmentÂ
US biopharmaceutical company Novavax has reorganised its senior management.
The changes see former executive chairman Stanley Erck take on the roles of president and chief executive, and current board member James Young start as chairman.
Stanley has been an active member of Novavax’s senior management team for the last year and has extensive biotech experience.
From 2000-2008 he served as president and chief executive of Iomai Corporation, leading the company through an initial public offering and a merger with Austrian vaccine company Intercell.
Prior to Iomai, he served as president and chief executive of immunology company Procept, as VP of corporate development at Integrated Genetics (now part of Genzyme), and in management positions within Baxter International.
James Young, who became a Board member in April 2010, has over 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development.
He was previously president of research and development, with responsibility for regulatory affairs, at MedImmune.
Prior to this served at Smith Kline & French Laboratories (now part of GlaxoSmithKline) rising to director of its molecular genetics department.
“As the Company continues its transition into a commercial operation, we are pleased to have attracted high caliber professionals such as Stan and Jim to now take the leadership roles at Novavax,” said Gary Evans, of Novavax’s Board of Directors.
“We expect these gentlemen will dynamically lead the company and its vaccine candidates towards important worldwide products. Their strong leadership skills and broad experience in drug development will be invaluable to Novavax as the Company works to advance its infectious disease pipeline of virus-like particle (VLP) vaccine candidates.”
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
